冠状动脉疾病中的心脏重塑

Cardiac remodeling in coronary artery disease.

作者信息

Sharpe Norman

机构信息

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

出版信息

Am J Cardiol. 2004 May 6;93(9A):17B-20B. doi: 10.1016/j.amjcard.2004.01.002.

DOI:10.1016/j.amjcard.2004.01.002

PMID:15144932

Abstract

Cardiac remodeling is a central mechanism of heart failure progression in patients with coronary artery disease (CAD). The remodeling effect of beta-blockade with carvedilol has been studied in patients with left ventricular dysfunction after myocardial infarction and in patients with chronic heart failure of ischemic etiology. Carvedilol has been found to prevent progressive adverse ventricular remodeling in both conditions. This effect is concordant with the improvement in long-term clinical outcomes established for carvedilol in such patients. Thus, ventricular remodeling appears to be an important treatment target in patients with CAD and is likely to mediate at least part of the clinical improvement achieved with carvedilol.

摘要

心脏重塑是冠心病（CAD）患者心力衰竭进展的核心机制。卡维地洛β受体阻滞剂的重塑作用已在心肌梗死后左心室功能不全患者以及缺血性病因的慢性心力衰竭患者中进行了研究。已发现卡维地洛在这两种情况下均可预防进行性不良心室重塑。这种作用与卡维地洛在此类患者中确立的长期临床结局改善相一致。因此，心室重塑似乎是CAD患者的重要治疗靶点，并且可能介导了卡维地洛所取得的至少部分临床改善。